Dendritic Mesoporous Organosilica Nanoparticles with Photosensitizers for Cell Imaging, siRNA Delivery and Protein Loading

Molecules. 2023 Jul 11;28(14):5335. doi: 10.3390/molecules28145335.

Abstract

Dendritic mesoporous organosilica nanoparticles (DMON) are a new class of biodegradable nanoparticles suitable for biomolecule delivery. We studied the photochemical internalization (PCI) and photodynamic therapy (PDT) of DMON to investigate new ways for DMON to escape from the endosomes-lysosomes and deliver biomolecules into the cytoplasm of cells. We added photosensitizers in the framework of DMON and found that DMON were loaded with siRNA or FVIII factor protein. We made four formulations with four different photosensitizers. The photosensitizers allowed us to perform imaging of DMON in cancer cells, but the presence of the tetrasulfide bond in the framework of DMON quenched the formation of singlet oxygen. Fortunately, one formulation allowed us to efficiently deliver proapoptotic siRNA in MCF-7 cancer cells leading to 31% of cancer cell death, without irradiation. As for FVIII protein, it was loaded in two formulations with drug-loading capacities (DLC) up to 25%. In conclusion, DMON are versatile nanoparticles capable of loading siRNA and delivering it into cancer cells, and also loading FVIII protein with good DLC. Due to the presence of tetrasulfide, it was not possible to perform PDT or PCI.

Keywords: FVIII factor; dendritic mesoporous organosilica nanoparticles; siRNA.

MeSH terms

  • Cell Line, Tumor
  • Humans
  • MCF-7 Cells
  • Nanoparticles* / chemistry
  • Photochemotherapy* / methods
  • Photosensitizing Agents / pharmacology
  • RNA, Small Interfering / metabolism

Substances

  • Photosensitizing Agents
  • RNA, Small Interfering

Grants and funding

This research received no external funding.